Clifford Courville, MD
Pulmonary Disease · Lake Charles, LANPI 1942461207
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,029 of the $14,524 with a category attached, or 75.9%. It is spread thinly across 41 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,773 and has fallen 64.2% since, to $1,707 in 2025.
Across 612 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Intuitive Surgical$3K
- AstraZeneca$1K
- Boehringer Ingelheim$901
- Sanofi$746
- Regeneron Healthcare Solutions, Inc.$516
- plus $5K from 35 others
What the payments were for
- Food & beverage$11,02976%
- Education$3,49524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 209 | $3,403 |
| Intuitive Surgical | 12 | $3,394 |
| AstraZeneca | 57 | $1,038 |
| Boehringer Ingelheim | 39 | $901 |
| Sanofi | 42 | $746 |
| Regeneron Healthcare Solutions, Inc. | 23 | $516 |
| CSL Behring | 21 | $463 |
| Insmed, Inc. | 18 | $460 |
| Baxter Healthcare | 12 | $365 |
| Sunovion Pharmaceuticals Inc. | 31 | $342 |
| Actelion Pharmaceuticals US, Inc. | 18 | $307 |
| Novartis | 13 | $267 |
| Amgen | 12 | $263 |
| United Therapeutics Corporation | 12 | $232 |
| Grifols USA, LLC | 13 | $231 |
| Philips North America LLC | 15 | $231 |
| Mylan Specialty L.p. | 12 | $191 |
| Genentech USA, Inc. | 10 | $169 |
| Sanofi-aventis U.S. LLC | 2 | $159 |
| Verona Pharma, Inc. | 5 | $117 |
| Gilead | 6 | $105 |
| Bayer | 5 | $98 |
| Covidien LP | 1 | $86 |
| ANI Pharmaceuticals, Inc. | 2 | $56 |
| Viatris Specialty LLC | 2 | $48 |
| Pfizer | 3 | $41 |
| Pulmonx Corporation | 2 | $39 |
| Vifor Pharma, Inc. | 1 | $26 |
| Abiomed | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| AbbVie | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Haemonetics Corporation | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,524 in reported general payments places this provider in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 67 | $848,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 616 | $493,464 |
| Dupixent PenDupilumab | 97 | $353,664 |
| AdempasRiociguat | 12 | $162,687 |
| Breo ElliptaFluticasone/Vilanterol | 292 | $129,296 |
| TezspireTezepelumab-Ekko | 27 | $112,144 |
| LetairisAmbrisentan | 14 | $110,998 |
| XolairOmalizumab | 28 | $95,389 |
| Orenitram ErTreprostinil Diolamine | 12 | $81,398 |
| EliquisApixaban | 109 | $74,166 |
| Spiriva RespimatTiotropium Bromide | 110 | $70,187 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 92 | $50,898 |
| Ambrisentan | 16 | $42,259 |
| SymbicortBudesonide/Formoterol Fumarate | 96 | $35,967 |
| Spiriva HandihalerTiotropium Bromide | 56 | $34,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $901 | $978,641284 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,403 | $691,2121,094 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Bevespi Aerosphere | $1,038 | $176,590175 claims |
| BayerAdempas | $98 | $162,68712 claims |
| GileadLetairis | $105 | $110,99814 claims |
| PfizerEliquis | $41 | $74,166109 claims |
| Johnson & JohnsonXarelto | $24 | $12,14423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lake Charles
- Gary KohlerLake Charles$21K
- Luke WilliamsLake Charles$16K
- Robert BroussardLake Charles$15K
- Tashfeen MahmoodLake Charles$14K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.